Circulating tumour cells (CTCs) provide a real-time window into cancer biology; offering critical insights into the molecular and cellular mechanisms that drive the disease.
Unlike circulating tumour DNA (ctDNA), CTCs are intact, viable cancer cells that provide real-time insights into tumour progression, evolution and treatment resistance. Their ability to deliver both molecular and functional information makes them invaluable for precision oncology.
The Vortex VTX-1 Liquid Biopsy System simplifies and automates the isolation and collection of clinically relevant, viable CTCs directly from whole blood.
The great advantage to us of the Vortex technology is the rapid, gentle, non-contact isolation of live CTCs for our analysis. The Vortex VTX-1 rapidly isolates the live cells in excellent condition, which we simply couldn’t do by other methods.
EMV Capital Acquires Controlling Stake in Vortex Biosciences, Fueling Liquid Biopsy Advancement
